The identification of the PCOS secondary to FPLD2 is important in clinical practice because these patients benefit from tailored therapies, including specific dietary management [19] as well as insulin sensitizers, particularly thiazolidinediones, which are PPARY agonists [15], and in some cases, by metreleptin therapy [20,21]. Here, INS is linked to polycystic ovary syndrome.